Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Nea Ionia – page 33

1 034 clinical trials in Nea Ionia, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Nea Ionia at a glance
1 034
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 034 trials in Nea Ionia

Open in trial search

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Amgen Inc.

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Haematological infection+1

Not yet recruiting

Evaluating ceftazidime and avibactam with rapid testing for patients with bloodstream infections, hospital-acquired pneumonia, or ventilator-associated pneumonia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Avibactam
  • Sponsor:National University Of Singapore

Efficacy and Safety of Sodium Valproate Added to Standard Therapy in Patients with Stable Pulmonary Arterial Hypertension – Phase 2b Randomized Study

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Valproate
  • Sponsor:Cereno Scientific AB

Cardiac failure

Not yet recruiting

Efficacy and Safety of Fixed‑Dose Combination of Dapagliflozin, Bisoprolol Fumarate, and Eplerenone vs Usual Care in Hospitalized Acute Heart Failure Patients

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Cardiac failure acute+1

Not yet recruiting

Efficacy of istaroxime versus placebo (sodium chloride) infusion in patients with cardiogenic shock due to acute heart failure

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Istaroxime
  • Sponsor:Seismic Pharmaceuticals Operations LLC

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Primary biliary cholangitis

Not yet recruiting

Saroglitazar hemimagnesium normalizes alkaline phosphatase in primary biliary cholangitis patients with incomplete response or intolerance to ursodeoxycholic acid

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

Other cities in Greece

The busiest research cities in the country

All 47 cities in Greece

Clinical research in Nea Ionia

What the registry says about research in the country

01 Cardiovascular Disease Management

Innovative research focusing on lipoprotein reduction and prevention of major cardiovascular events in patients with established CVD. Studies evaluate new therapeutic approaches for reducing cardiovascular risks.

  • Cardiovascular event prevention
  • Lipoprotein management
  • Heart disease treatments

Advanced trials exploring novel compounds for improved patient outcomes.

02 Atrial Fibrillation Treatment

Comprehensive studies examining various approaches to manage atrial fibrillation, including new medications for stroke prevention and cardiac rhythm control.

  • Stroke prevention therapies
  • Cardioversion treatments
  • Anticoagulation management

Multiple therapeutic options being evaluated for different patient populations.

03 Heart Failure Research

Investigation of innovative treatments for chronic heart failure, focusing on patients with reduced ejection fraction and those with kidney complications.

  • Medication effectiveness studies
  • Combined therapy approaches
  • Cardiovascular outcomes

Evaluating new therapeutic combinations to improve patient survival and quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.